Grants for Public and State controlled institutions of higher education - Health

This funding opportunity supports short courses that train researchers in advanced mental health research skills, targeting graduate students, postdoctoral scholars, and early-career investigators across the nation.

The Regional Opportunity Initiatives (ROI) is offering a second round of Digital Towns Grant funding to implement strategies that improve digital equity and inclusion across the Indiana Uplands. The program aligns with ROI's mission to advance a more digitally inclusive region by integrating digital information and communication into all aspects of communities. This grant is designed to support projects and programs that ensure Uplands citizens can fully participate in a digital society, going beyond just broadband expansion to include access to affordable internet, reliable devices, and sufficient digital skills and literacy. The target beneficiaries of this grant program are Uplands communities and organizations within the 11-county Indiana Uplands region, including incorporated cities and towns, county commissions and councils, libraries, nonprofits, public education institutions, faith-based organizations, Main Street organizations, chambers of commerce, economic development organizations with an affiliated 501(c)3, and organizations/programs that help businesses/entrepreneurs. The impact goal is to increase the digital capabilities of the region, ensuring everyone has the resources and skills to prosper in the digital age. The program focuses on three main themes: Digital Citizens, Digital Public Services, and Digital Business. Digital Citizens aims to help households connect to the internet, access devices, and grow competence in using digital technologies for internet services, e-commerce, educational opportunities, digital public services, and healthcare. Digital Public Services supports collaborations between local government, nonprofits, and healthcare to provide access to online information, services, and telehealth. Digital Business partners with businesses and entrepreneurs to maximize opportunities in the digital economy. Expected outcomes include financially supported projects that align with the Indiana Uplands Digital Inclusion Plan, leading to a more digitally inclusive region. Measurable results will be seen in increased access to affordable internet, reliable devices, and improved digital skills and literacy among citizens, as well as enhanced e-commerce opportunities for local businesses and improved access to digital public and healthcare services. ROI's strategic priority is to advance regional digital capabilities through funding for professional services, training, digital products, equipment/hardware, and other services that promote digital inclusion and prosperity. Applicants can receive between $5,000 and $50,000, with regional scope projects eligible for up to $75,000.

This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative.Funding Opportunity Description Background This Funding Opportunity Announcement (FOA) is issued in response to National Alzheimer's Project Act (NAPA) milestones for the genetics of Alzheimer's disease (AD) and AD-related dementias (ADRD) in order to support the ongoing Alzheimer's Disease Sequencing Project (ADSP). The overarching goals of the ADSP are to: 1) identify new genes involved in AD/ADRD; 2) identify gene alleles contributing to increased risk for, or protection against, the disease; 3) provide insight as to why individuals with known risk factor genes escape from developing AD/ADRD; 4) identify potential avenues for therapeutic approaches and prevention of the disease; and 5) fully reveal the genetic architecture of AD/ADRD in multiple race and ethnicity categories. The samples for the ADSP were selected from well-characterized, diverse study cohorts of individuals both with and without an AD diagnosis as well as with and without known risk-factor genes. This study of human genetic variation and its relationship to health and disease involves a large number of study participants and aims to capture not only common single nucleotide variations, but also rare copy number and other structural variants that are increasingly thought to play an important role in complex diseases. This FOA uses the Office of Management and Budget (OMB) official categories of race and ethnicity. For the purposes of this FOA, ethnic categories (i.e., Hispanic/Latino) and racial categories (i.e., American Indian/Alaska Native; Asian; and Black/African American) will be referred to as diverse populations . Cohorts of participants from individual ethnic or race categories will be referred to as diversity cohorts . Individuals in diversity cohorts will be referred to as diversity participants . The ADSP has identified a large number of variations in the genomes of individuals affected with AD. The study population for these analyses was predominantly White. Lack of diversity in the sample set limits the possible clinical utility of emerging tools and methodological approaches for identifying potential therapeutics for a large proportion of the population. This, in turn, underscores the urgency to ensure appropriate representation of diverse populations to prevent potential gaps in the translation of research efforts to these populations. To this end, the initial ADSP findings will be pursued in diverse populations in the next phase of the study, called the ADSP Follow-Up Study (FUS) 2.0: The Diverse Population Initiative and referred to here as ADSP FUS 2.0. The long-term goals of the ADSP FUS 2.0 are to: 1) move the field closer to enabling prediction of who will develop AD; 2) fully characterize AD subtypes by studying endophenotypes in diverse populations; 3) better understand the differences in the genetic underpinnings of AD pathogenesis among diverse populations; and 4) identify specific therapeutic targets based upon diverse population. Important instances of unique AD/ADRD genetic variation have already been identified in epidemiological cohorts with Hispanic/Latino and Black/African American participants. Variants for AD are rare and can only be identified with a larger number of study participants. Variants occur at different frequencies in different populations, and certain risk variants may be much easier to detect in some populations. US diversity groups are not represented in ADSP data in sufficient numbers to enable meaningful study, so the genetics of these populations remain largely unstudied. Hispanics/Latinos, Blacks/African Americans, and Asians are the largest and fastest-growing minority groups in the US, and AD/ADRD imposes a high economic and social burden upon the US population. US Asian population ADSP genetic data are completely absent. Numbers of Hispanic/Latino and Black/African American participants in the US remain insufficient to provide statistical significance for identification of rare or very rare variants. Variants in the Alzheimer’s genome are largely rare or very rare in the population. It is estimated that for 80% certainty for single variant testing for rare variants, ~16,100 cases and ~16,100 controls are needed for a variant with a minor allele frequency of 0.5% in the population; single variant testing for rare variants indicate that for 90% certainty, ~18,500 cases and ~18,500 controls are needed for each population for a variant with a minor allele frequency of 1% in the population. To ensure that there are sufficient numbers of study participants to achieve statistical power for analysis of rare or vary rare variants in the three largest diversity cohorts AD/ADRD genome given the available funding, the primary focus of the ADSP FUS 2.0 will be on Hispanic/Latino, Black/African American, and Asian populations. Consortia should take advantage of cohorts already recruited or in planning for recruitment to obtain sufficient numbers; sharing diversity data across consortia is essential to the success of this effort. Investigators with cohorts representing other racial/ethnic categories, such as American Indians/Alaskan Natives, are encouraged to apply for funding separately under other NIA-supported FOAs. Sequencing of participants from founder populations such as those from Africa and Asia is allowed under this FOA in order to understand population substructure and ancestry-informative markers. A small amount of sequencing of Whites to bring significance to the 90% certainty of significance level will be allowed for rare or very rare variants for the US population; however, it is expected that the vast majority of sequencing in the ADSP FUS 2.0 will be done in Hispanics/Latinos, Blacks/African Americans, and Asians. Accelerated identification of AD/ADRD genes, gene clusters, and endophenotypes driven by genetic and ethnic/racial characteristics will move the field toward selection of participants with similar endophenotypes to improve outcomes of clinical trials. The community is now able to layer different types of data to identify these endophenotypes. Analytic approaches are being developed for analysis of structural and rare variants, endophenotypes, and cross-phenotype genetic analyses to modify and/or apply analytic methods to data that are increasingly complex. In order to identify optimal drug targets, the full landscape of genetic variants must be identified and characterized. Much work remains to develop analytic methods and resources to understand the functional significance of variants, particularly noncoding variants, in diverse populations. Under this funding opportunity announcement, studies that perform analysis of sequence data may include analysis of the functional genomic studies of regions of interest. Diversity datasets will need to be integrated and harmonized to fully annotate the AD genome. This may mean assembling annotation data such as that provided by ENCODE and similar approaches to help understand whether clusters of genes in the same network or with common function may be a component of the disease etiology that varies by ethnic and racial category. Applicants are encouraged to devise analysis plans to include data from genome wide association studies (GWAS) for AD; imputation analysis; ADSP whole exome and exome chip data, and whole genome AD sequencing efforts; related genetic data such as in deep (long read) sequencing analyses generated on AD subjects; and functional genomics data. Research Objectives NIA intends to support studies most likely to meet a major goal of this FOA: to identify and confirm a full set of rare variants contributing to AD/ADRD endophenotypes in diversity cohorts to enhance the probability of identifying potential therapeutic approaches for risk and prevention. Both sequencing and data analysis will be supported under this FOA. Applicants to this FOA for the ADSP FUS 2.0 should propose to: 1) sequence particular diverse study cohorts; 2) analyze either the entire dataset (cases and controls) or components of the dataset; or 3) both sequence and analyze these data. Justification for the choice of the approach must be provided. Applicants proposing to analyze only a component of the total cohort (i.e., selected cohorts or diverse subpopulations) should propose power calculations that support the likelihood of gene discovery. Applicants should design plans that clearly define which ADSP FUS 2.0 datasets, diverse subpopulations, and/or endophenotypes will be analyzed. Along with analysis of data funded under the present FOA, analysis plans for the ADSP FUS 2.0 should include data from diversity cohorts in the ADSP FUS funded under PAR-17-214, PAR-18-890, and PAR-19-234 where possible. The design and use of large-scale storage capacity with appropriate security and backup measures to support analytical capabilities should be considered. Successful applications are anticipated to involve research conducted by multidisciplinary teams of investigators and should describe a comprehensive plan to develop leading-edge, innovative approaches for the analysis of whole genome sequence (WGS) and related genetic data. Analysis should encompass the criteria set out by the ADSP FUS funded under PAR-17-214, "Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01)." In particular, these criteria include ethnic/racial diversity; autopsy-confirmed cases/controls, especially for non-European ancestry; availability of longitudinal data; no age limit for cases; cases unrelated to each other; and availability of comparable controls. It is expected that the scientific environment in which the work will be done will contribute to the probability of success of the project and of the ADSP as a whole. Institutional support, equipment and other physical resources available to the investigators should be adequate for the project proposed, leveraging existing NIA-funded resources. Both the project itself and the ADSP should benefit from unique features of the scientific environment, subject populations, or collaborative arrangements. For applicants performing data analysis, it is expected that they will have the capacity to analyze whole-genome sequence data from sufficient numbers of affected and unaffected individuals to achieve statistical significance for rare or very rare variants in diverse groups. The successful milestone-driven ADSP FUS 2.0 application would consist of a group of researchers with expertise in the genetics of complex neurological diseases, including AD, and the field of whole genome sequencing, as well as statisticians and other experts who will participate in study design and analysis. Successful applicant(s) may be expected to collaborate not only within their own study, but also with other PD(s)/PI(s) funded under this and related FOAs. Engagement of existing NIA-supported infrastructure is considered essential to the success of the project, so applicants should plan to financially support the National Central Cell Repository for Alzheimer’s Disease (NCRAD); The American Genome Center (TAGC) at the Uniformed Services University for the Health Sciences (USUHS) or another NIA-approved, large-scale sequencing center; the Genome Center for Alzheimer's Disease (GCAD); and the NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) for their efforts in the ADSP. Applicants should develop key quantitative milestones with a timeline for accomplishment. Quality control (QC) and data harmonization will be performed by GCAD. The order and process for data transfer, quality control checking, and data harmonization will be agreed upon by the ADSP as a whole and will follow closely the existing paradigm. Under the present FOA, the ADSP will improve the likelihood of analyzing sequence data on enough different examples of events that change the genetic architecture of AD such that these data, when analyzed with existing ADSP datasets, will enhance the ability to better understand the genetic underpinnings of AD and to obtain a better understanding of rare risk and protective variants. The availability of high-quality, extensive phenotypic information on study participants is a critical consideration. Study design should include analysis of data from study participants with quantitative trait measures to more clearly define endophenotypes. Similarly, participants whose data will be used as controls should be well characterized. Applications considered for funding must effectively leverage NIA and NIH investments in infrastructure to support studies related to the genetics of Alzheimer’s disease. The investigators funded under this FOA may utilize information from existing NIA- and NIH-funded research resources or other federal websites such as: The NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) The Genome Center for Alzheimer's Disease (GCAD) The National Central Cell Repository for Alzheimer’s Disease (NCRAD) The National Alzheimer's Coordinating Center (NACC) The Alzheimer's Disease Genetics Consortium (ADGC) The Alzheimer's Disease Research Centers (ADRCs) Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) The Collaborative for Alzheimer’s Disease Research (CADRE) The Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer's Disease Related Dementias (ADRD) The National Alzheimer’s Project Act (NAPA) Other websites designed to store and distribute data related to AD

This grant provides funding to organizations that will educate and promote financial support for living organ donors, particularly in underserved communities, to increase awareness and access to organ donation services.

This funding opportunity provides financial support for research projects that develop and test nonopioid pain management strategies for Veterans and military personnel, focusing on integrating these approaches into standard healthcare practices.

This funding opportunity supports research projects that develop and test innovative interventions for individuals with substance use disorders involved in the criminal justice system, particularly focusing on improving treatment access and outcomes in diverse settings.

This funding opportunity supports early-career researchers and medical residents conducting impactful cancer research relevant to military health, with a focus on improving the quality of life for service members and their families.

This grant provides funding for research on how climate change impacts cancer prevention, treatment, and survivorship, targeting a wide range of organizations including governments, universities, and nonprofits.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on diabetes, its complications, and related endocrine and metabolic diseases. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the P30 activity code. Details of the planned NOFO are provided below.

The "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes" grant aims to fund research projects that prepare for clinical trials in rare diseases by developing effective strategies for testing potential treatments or diagnostics, improving success rates with robust biomarkers and assessment measures, or by understanding the progression of a rare disease to better design future clinical trials.

This funding opportunity provides financial support to a variety of organizations to strengthen Ghana's public health system, focusing on improving disease prevention, detection, and response capabilities.

This funding opportunity supports research projects that advance the use of genomic information in clinical care, particularly for diverse and underserved populations, by providing financial assistance to a range of eligible organizations.

This grant provides funding for innovative research aimed at understanding the biological and immunological factors that contribute to the increased susceptibility of transgender individuals to HIV and other sexually transmitted infections.

The grant titled "Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA)" aims to enhance biomedical engineering and technology capacity at HBCUs by providing funding for research infrastructure, academic training, and technology innovation over two phases.

The purpose of this notice of funding opportunity (NOFO) is to invite applications for Research Centers (RC) to support the Centers for Research in Emerging Infectious Diseases (CREID) Network. The CREID network serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur. Multi- and inter-disciplinary teams of domestic and international investigators will conduct innovative, collaborative One Health (approach that recognizes the health of humans is interconnected with that of animal health and the shared environment) based research projects and will mount a rapid and effective research response to outbreaks through coordination, collaboration, and cooperation across the CREID Network.

The PATH Foundation’s **Better Together Fund** is designed to strengthen community connections by supporting local events that bring people together in celebration, collaboration, and shared purpose. Established in 2021, the fund reflects PATH’s mission to enhance the quality of life in Virginia’s Piedmont region by fostering engagement, well-being, and unity among residents. Through this program, the foundation aims to make small but meaningful investments in events that inspire belonging and reinforce the social fabric of local communities. Eligible nonprofits and organizations operating in **Fauquier, Rappahannock, and Culpeper counties** may apply for grants of up to **$2,500 per event**. Funding can be used to support a wide variety of community-facing gatherings—such as festivals, cultural celebrations, educational activities, and other inclusive events that encourage participation and connection among local residents. The initiative is particularly focused on efforts that celebrate diversity, build relationships, and create shared experiences that strengthen the sense of community. To qualify, events must take place within one year of submission and comply with all applicable health and safety guidelines. Applicants must be recognized 501(c)(3) nonprofit organizations, educational institutions, religious institutions, or local government entities. The program’s flexible structure allows for a broad range of creative and community-driven ideas, ensuring that small towns and neighborhoods have the opportunity to host meaningful events that align with PATH’s goal of cultivating healthier, more connected communities. While the grant duration is not specified, the funding operates on a rolling basis, emphasizing timeliness and local relevance. Events supported by the Better Together Fund are intended to be accessible, inclusive, and beneficial to the broader public rather than serving narrow organizational or private interests. The fund’s straightforward application process encourages both established and smaller community groups to apply, removing barriers for those who may not typically pursue grant funding. Through the Better Together Fund, the PATH Foundation continues to champion collaboration and social cohesion as essential pillars of community health. By investing in shared experiences that unite people across backgrounds, the foundation underscores its belief that thriving communities are built not just through infrastructure and services—but through connection, empathy, and collective joy.

This funding opportunity provides financial support for researchers and organizations to develop and validate innovative technologies that improve the understanding and treatment of cancer, with a focus on addressing unmet needs and health disparities.

This funding opportunity provides financial support to various organizations and governments to develop and implement trauma-informed services for children affected by violence in their homes, schools, and communities.

The National Cancer Institute intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for pilot/exploratory research on the confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This NOFO will utilize the R21 grant mechanism (clinical trial optional), which is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Up to three (3) R21 awards are expected to be funded as part of the initiative. Research projects will advance the current understanding of the confluence of cancer stigma and HIV stigma in people with HIV (PWH) diagnosed with cancer; investigate the resultant impact of these dual stigmas on cancer outcomes among PWH with cancer; and promote research in diverse domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. Pilot interventional research, which addresses modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer, is also suitable for this funding mechanism. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 39 minutes. Presentation slides are downloadable at: https://deainfo.nci.nih.gov/advisory/joint/0624/Vanderpool.pdf.

This funding opportunity supports U.S. colleges and universities in developing programs that enhance diversity and provide research training for undergraduate students from underrepresented groups, preparing them for advanced biomedical research careers.